首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 93 毫秒
1.
目的 研究鼻咽癌患者外周血细胞因子诱导的杀伤细胞(CIK)的增殖能力、对鼻咽癌细胞株HONE1的细胞毒作用,寻求鼻咽癌过继免疫治疗的新途径。方法 提取24例鼻咽患者外周血单个核细胞,用IFN-γ、抗CD3mAb、IL-2和IL-1β共同培养诱导CIK细胞,计数不同时间点的细胞数,用MTT法检测细胞对鼻咽癌细胞株HONE1的杀伤活性,用ELISA法测定CIK细胞分泌种细胞因子的水平,同时培养CD3AK细胞和LAK细胞,与CIK细胞在增殖和杀瘤活性上进行比较。资料用SPSS13.0软件进行分析,P<0.05为统计有差异性。结果 鼻咽癌患者CIK细胞表现出很强的体外增值活性及杀瘤活性,与CD3AK细胞和LAK细胞相比,其增殖活性和对鼻咽癌细胞株HONE1的杀伤活性均明显提高(P<0.05),且与正常人自体CIK细胞相比无明显差别(P>0.1)。结论 鼻咽癌患者CIK细胞体外增殖能力和杀瘤活性明显优于CD3AK和LAK细胞,为鼻咽癌患者的临床过继免疫治疗提供了一种新的有效地治疗手段。  相似文献   

2.
CD3AK、LAK与CIK细胞生物学特性的研究   总被引:2,自引:0,他引:2  
①目的探讨CD3AK、LAK及CIK细胞的诱导、增殖能力及杀伤活性的变化.②方法采用CD3单抗和IL-2刺激诱生扩增CD3AK细胞,用IL-2刺激诱生LAK细胞,采用第0天加入IFN-γ,第1天加入IL-1,CD3单抗,IL-2诱生CIK细胞,观察它们的扩增情况;用MTT法以K562和H7402细胞为靶细胞,测定CD3AK、LAK及CIK细胞的杀伤活性.③结果CD3AK和CIK细胞的扩增能力远大于LAK细胞(P<0.05).CIK细胞和CD3AK相比,在前期无明显差异,至第19、22天时CIK细胞的扩增能力显著高于CD3AK的扩增倍数(P<0.05).CD3AK和CIK细胞对K562和H7402细胞的杀伤活性均显著高于LAK细胞(P<0.05).④结论CIK细胞具有更高的扩增能力和更强的杀伤活性,是肿瘤过继免疫治疗中更为有效的杀瘤效应细胞.  相似文献   

3.
CIK细胞的制作及对不同肿瘤细胞株体外抗肿瘤作用的研究   总被引:13,自引:0,他引:13  
目的:制备细胞因子激活杀伤(CIK)细胞并观察其生物学特性及对不同肿瘤细胞株的杀伤作用.方法:外周血单个核细胞用无血清培养基经干扰素γ(IFN-γ),CD3McAb,白介素2(IL-2),白介素1α(IL-1α)诱导,制作CIK细胞,以淋巴因子激活的杀伤细胞(LAK)作为对照,流式细胞仪检测CIK细胞的免疫表型,MTT法检测其对不同肿瘤细胞株的杀瘤活性.结果:CIK细胞与LAK细胞相比增殖速度快、最终增殖倍数高.CIK细胞主要由CD3和CD56双阳性细胞构成.CIK细胞对多种肿瘤细胞具有较强的杀伤活性.结论:CIK细胞过继免疫治疗是一种非常有前景的抗肿瘤治疗方法.  相似文献   

4.
恶性肿瘤患者自体CIK细胞的实验研究   总被引:1,自引:0,他引:1  
目的通过比较CIK细胞和LAK细胞的增殖、表型和抗瘤效应,为临床应用CIK细胞过继免疫治疗提供资料。方法取12例恶性肿瘤患者外周血,常规分离成单个核细胞,用不同细胞因子培养诱导出LAK细胞和CIK细胞,观察两种细胞的增殖、表型和抗瘤效应。结果培养后12天,CIK细胞数量达原来的11.5倍,而LAK细胞数量只有原来的5.2倍;比较培养前后CIK细胞的表型,可发现CD3+、CD3+CD4+、CD3+CD8+、CD3+CD56+、CD25+在培养后均有明显增高(P<0.05或0.001)。CIK细胞杀伤K562细胞和Raji细胞的能力均明显优于LAK细胞(P<0.05或0.001)。结论CIK细胞不仅具有强大的增殖功能,并且对不同的肿瘤细胞系显示出较LAK细胞更强的杀伤活性。因此,它是一种新型的过继免疫治疗方法。  相似文献   

5.
细胞因子诱导的杀伤细胞体外扩增及其生物学特性的研究   总被引:1,自引:0,他引:1  
目的:观察细胞因子诱导的杀伤细胞(CIK)的体外增殖能力及其生物学特性。方法:取正常成人新鲜血,经密度梯度离心法,利用连续非贴壁的方法获得单个核细胞(PBMC),加入不同的细胞因子(IFN-γ、IL-1β、IL-2、CD3mAb),诱导生成CIK细胞,以LAK细胞作为对照。观察CIK细胞的扩增情况,用流式细胞仪检测其表面标志,MTT法测定其杀瘤活性。结果:诱导16d后,CIK细胞的增殖率达到高峰,具有较强的扩增能力,经过22d培养,总的细胞数可扩增至100多倍;CIK细胞和LAK细胞相比,在前期无明显差异,至18、21d时扩增能力显著高于LAK细胞的扩增倍数(P<0.01)。CIK细胞是一群异质细胞群,CD3 CD56 细胞为其主要的效应细胞,经过22d培养显著增加,为(55.15±5.49)%,其绝对值可增加1500多倍。CIK对A-549细胞的杀伤活性均显著高于LAK细胞(P<0.05),具有较强的杀瘤能力。结论:CIK细胞具有较强的扩增和杀瘤能力,是肿瘤过继免疫治疗中更为有效的杀瘤效应细胞。  相似文献   

6.
MtbAK细胞与CD3AK、LAK细胞体外增殖和杀瘤活性比较   总被引:4,自引:1,他引:3  
目的:比较结核杆菌抗原激活的杀伤细胞(Mtb AK)、CD3AK及LAK细胞的体外增殖能力和杀瘤活性.方法:分别用结核杆菌抗原(Mtb-Ag)、CD3 mAb和rIL-2刺激人外周血单个核细胞(PBMC),在含rIL-2的RPMI 1640培养液中诱导扩增MtbAk、CD3AK和LAK细胞,用计数法动态观察细胞扩增情况,在流式细胞仪上分析MtbAK中的γδ T细胞比例,以MTT法检测三种扩增细胞对肿瘤细胞的细胞毒活性.结果:与CD3AK和LAK细胞相比,MtbAK细胞具有更强的增殖能力和较高的细胞毒活性.结论:MtbAK细胞在体外更易于扩增,具有较高的杀瘤活性,有可能应用于肿瘤患者的临床过继免疫治疗.  相似文献   

7.
MtbAK细胞与CD3AK、LAK细胞全外增殖和杀瘤活性比较   总被引:13,自引:5,他引:8  
目的:比较结核杆菌抗原激活的杀伤细胞(MtbAK)、CD3AK及LAK细胞的体外增殖能力和杀瘤活性。方法:分别和结核杆菌抗原(Mtb-Ag)、CD3 mAb和rIL-2刺激人外周血单个核细胞(PBMC),在含rIL-2的RPMI1640培养液中诱导扩增MtbAK、CD3AK和LAK细胞,用计数法动态观察细胞扩增情况,在流式细胞仪上分析MtbAK中的γδT细胞比例,以MTT法检测三种扩增细胞对肿瘤细胞的细胞毒活性。结果:与CD3AK和LAK细胞相比,MtbAK细胞具有更强的增殖能力和较高的细胞毒活性。结论:MtbAK细胞在体外更易于扩增,具有较高的杀瘤活性,有可能应用于肿瘤患者的临床过继免疫治疗。  相似文献   

8.
目的观察细胞因子诱导的杀伤细胞(CIK)的体外增殖能力及其生物学特性.方法取正常成人新鲜血,经密度梯度离心法,利用连续非贴壁的方法获得单个核细胞(PBMC),加入不同的细胞因子(IFN-γ、IL-1β、IL-2、CD3mAb),诱导生成CIK细胞,以LAK细胞作为对照.观察CIK细胞的扩增情况,用流式细胞仪检测其表面标志,MTT法测定其杀瘤活性.结果诱导16 d后,CIK细胞的增殖率达到高峰,具有较强的扩增能力,经过22 d培养,总的细胞数可扩增至100多倍;CIK细胞和LAK细胞相比,在前期无明显差异,至18、21 d时扩增能力显著高于LAK细胞的扩增倍数(P<0.01).CIK细胞是一群异质细胞群,CD3 CD56 细胞为其主要的效应细胞,经过22 d培养显著增加,为(55.15 5.49)%,其绝对值可增加1500多倍.CIK对A-549细胞的杀伤活性均显著高于LAK细胞(P<0.05),具有较强的杀瘤能力.结论CIK细胞具有较强的扩增和杀瘤能力,是肿瘤过继免疫治疗中更为有效的杀瘤效应细胞.  相似文献   

9.
目的 研究细胞因子诱导的杀伤细胞(CIK cells)的体外扩增特性及其在抗肿瘤免疫治疗中的作用.方法通过提取健康供血者的PBMNC,培养诱导CIK细胞,显微镜下观察其扩增倍数、增殖速率,流式细胞仪分析细胞免疫表型,用MTT法观察其对K562细胞的体外杀伤效应,并通过流式细胞仪进一步分析30例实体瘤患者CIK细胞输注前后外周血免疫活性细胞表型的改变.结果 经2周培养,CIK细胞平均增加了30倍,总数达(4.8~5.0)×109,活性细胞比例>90%;体外杀伤率约50%,表型检测效应细胞CD3+,CD3+CD4+、CD3+CD8+、CD3+CD56+亚群比例显著升高,差异有高度统计学意义(P<0.01).实体瘤患者CIK细胞输注后外周血中免疫活性细胞比例也明显升高,差异也有统计学意义(P<0.05).结论 CIK细胞在体内外能明显抑制肿瘤生长,有效改善患者的免疫功能,为晚期肿瘤治疗提供了新的方法.  相似文献   

10.
为比较CD3AK细胞和LAK细胞的杀瘤特性,观察了妇科肿瘤患者CD3AK细胞和LAK细胞对卵巢癌细胞系(3AO)的杀伤活性。结果表明:良性肿瘤组LAK细胞杀瘤活性高峰在培养第1、2周,显著高于同期培养的CD3AK细胞(P<0.05,P<0.01),第3周则较低,而CD3AK细胞的杀瘤活性高峰在培养第3、4周,显著高于LAK细胞(P<0.05);恶性肿瘤组,LAK细胞杀瘤高峰在培养第1周,显著高于同期培养的CD3AK细胞(P<0.05),而CD3AK细胞杀瘤高峰在培养第2、3周,显著高于同期培养的LAK细胞(P<0.05)。提示:妇科恶性肿瘤组LAK细胞和CD3AK细胞杀瘤活性高峰均较妇科良性肿瘤早1周左右;CD3AK细胞杀瘤活性高峰较LAK细胞延迟1~2周。说明CD3AK和LAK细胞的杀瘤活性在不同培养阶段表现不同,LAK细胞宜短期培养,CD3AK细胞宜长期培养。  相似文献   

11.
Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P < 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (>0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P <0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P < 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.  相似文献   

12.
Objective: To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods: SD rats served as both donors and recipients. 4℃ sodium lactate Ringer's was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava (IVC) inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results: Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion: This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.  相似文献   

13.
FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…  相似文献   

14.
Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P< 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P< 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.  相似文献   

15.
Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.  相似文献   

16.
In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.  相似文献   

17.
Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.  相似文献   

18.
目的:评价使用安心颗粒对急诊经皮冠状动脉介入术(PPCI)术后生活质量的影响.方法:将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组(术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次)和对照组(仅接受基础药物治疗).所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表(MIDAS)、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果:入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异(P>0.05);出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低(P<0.05);组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低(P<0.05).两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血(P>0.05).两组发生轻度血小板减少症的患者数比较无差异(P>0.05).结论:PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.  相似文献   

19.
Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P<0.01);the MAP decreased(P<0.01)and the HR increased drastically(P<0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.  相似文献   

20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号